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Abstract
Objective: Depression may occur in up to 30% of individuals with cutaneous lupus 
erythematosus (CLE), many of whom may also have systemic manifestations. Compared to acute 
and subacute, chronic cutaneous lupus erythematosus (CCLE) conditions are less likely to present 
systemic involvement, but more often cause permanent scarirng and dyspigmentation. Little is 
known, however, about depression in those who have CCLE confined to the skin (primary CCLE). 
As African Americans are at high risk for primary CCLE and depression, we aimed to investigate 
the prevalence and explore risk factors of depression in a predominantly Black population-based 
cohort of patients with primary CCLE.
Methods: Cross-sectional analysis of a cohort of individuals with a documented diagnosis of 
primary CCLE, which is established in the metropolitan Atlanta. Participants were recruited from 
the Centers for Disease Control and Prevention (CDC) population-based Georgia Lupus Registry, 
multi-center dermatology clinics, community practices, and self-referrals. The Patient Reported 
Outcomes Measurement Information System (PROMIS) was used to measure the primary 
outcome: depressive symptoms. Stand-alone questions were used to assess sociodemographics and 
healthcare utilization. Emotional, informational, and instrumental support were measured with 
PROMIS short forms, interpersonal processes of care with the IPC-29 Survey, and skin-related 
quality of life with the Skindex-29+ tool.
Results: Of 106 patients, 92 (86.8%) were female, 91 (85.8%) Black, and 45 (42.9%) 
unemployed or disabled. Twenty-eight (26.4%) reported moderate to severe depressive symptoms. 
Depression severity was lower in patients aged ≥60, married, or college-graduated. Univariate 
analysis showed that being employed (OR=0.24, 95% Confidence Interval (CI)=0.10-0.61), 
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insured (OR=0.23, 95%CI=0.09-0.60), reporting higher instrumental, informational, and 
emotional support (OR=0.94, 95%CI=0.90-0.99; OR=0.91, 95%CI=0.87-0.95; and OR=0.86, 
95%CI=0.81-0.92, respectively), visiting a primary care physician in the last year (OR=0.16, 
95%CI=0.04-0.61) and reporting better physician-patient interactions (OR=0.56, 
95%CI=0.37-0.87) were negatively associated with depression. Patient’s perceptions of staff 
disrespect (OR=2.30, 95%CI=1.19-4.47) and worse skin-related quality of life (OR=1.04, 
95%CI=1.02-1.06) rendered higher risk. In multivariate analysis, only perception of staff 
disrespect (OR=2.35, 95%CI=1.06-5.17) and lower emotional support (OR=0.48, 
95%CI=0.35-0.66) remained associated with depression.
Conclusions: Over one quarter of a predominantly Black population-based cohort of individuals 
with primary CCLE reported moderate to severe depression, a rate 3 to 5 times higher than those 
described previously in the general population from the same metropolitan Atlanta area. Our 
findings suggest that while patient’ perceptions of discrimination in the healthcare setting may 
play a role as determinant of depression, social support may be protective. In addition to routine 
mental health screening and depression treatment, patients with CCLE and depression may benefit 
from interventions directed to provide emotional support and improve office staff interpersonal 
interactions.
1. Introduction
Dermatologic diseases can negatively influence health-related quality of life (QoL) and are 
associated with psychiatric comorbidity. Between 10-30% of patients with a dermatologic 
disease have depression, compared to 4-20% in the general population, and severe skin 
lesions increase the risk of suicidal ideation [1–5]. Despite these clinically significant 
associations, physicians treating patients with cutaneous disease have low sensitivity in 
detecting psychiatric disorders [4]. Depression also occurs in 20-60% of patients with 
systemic lupus erythematosus (SLE), compared to 10% in the general population [6–8], and 
skin manifestations have been found to be independently associated with depression in SLE 
[9]. However, depression has not been well characterized in isolated cutaneous lupus 
erythematosus (CLE).
Cutaneous lupus erythematosus (CLE) encompasses multiple conditions classified into acute 
(ACLE), subacute (SCLE), and chronic (CCLE) [10]. Research on primary CLE (CLE 
without systemic involvement) is scarce despite recent reports suggesting a higher incidence 
of primary CLE compared to SLE [11–13].
A recent French study examined mental health conditions in a sample of 74 patients with 
CCLE and 26 with SCLE restricted to the skin and showed a 44% lifetime prevalence of 
clinical depression [14]. A study in the U.S. indicated that 26.5% of patients with CLE seen 
in a dermatology clinic had depressive symptoms in need of psychiatric intervention [2]. 
Using self-reported data from a U.S. national household sample, a recent study estimated a 
29.5% prevalence of depression among people with CLE [15], and a nationwide Danish 
study found a 2-fold increased risk of depression in individuals with CLE compared to the 
general population [16]. While these studies pointed to a high rate of depressive symptoms 
among people living with CLE, none accounted for potential differences in depression risk 
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across CLE conditions. Moreover, for CLE cases with associated SLE, whether the 
occurrence of depression was the consequence of systemic inflammation, as opposed to the 
primary skin condition was not determined.
CCLE is the most common subtype of CLE, making up 60-80% of CLE patients [11, 17]. 
Patients often exhibit greater skin damage and are less likely to present systemic 
manifestations compared to other CLE types [10, 18, 19]. Discoid lupus erythematosus 
(DLE), the hallmark of CCLE, often causes facial and body disfigurement, which could 
increase the risk of depression [10, 20]. However, little is known about the burden and risk 
factors of depression in patients with CCLE restricted to the skin.
Additionally, studies examining CCLE have included predominantly White subjects [18, 20, 
21], despite recent findings indicating that Black individuals have higher susceptibility for 
this condition and experience earlier damage compared to White individuals [22, 23]. We 
examined the prevalence and severity of depressive symptoms in a population-based cohort 
of patients with primary CCLE from the Southeast U.S. Additionally, we explored 
demographic characteristics, socioeconomic resources, healthcare and disease-related factors 
associated with depression in this population.
2. Methods
2.1. Population
We conducted a cross-sectional analysis of data collected among patients with primary 
CCLE (DLE, lupus panniculitis [LEP], lupus tumidus [LET]), enrolled in the longitudinal 
Georgia Organized Against Lupus (GOAL) cohort. GOAL is a population-based cohort of 
predominantly Black individuals with lupus from the Southeast U.S. Details of recruitment 
and data collection have been published previously [24]. GOAL initially enrolled patients 
with SLE, primarily derived from the Georgia Lupus Registry (GLR). GLR is a population-
based registry funded by the Centers for Disease Control and Prevention (CDC) designed to 
more accurately estimate the incidence and prevalence of SLE in metropolitan Atlanta, 
Georgia, where there is a large and socioeconomically diverse Black/White population [24, 
25]. In 2014, GOAL received funding from the CDC to further enroll patients with CCLE or 
SCLE. Sources of recruitment of CLE patients have been the GLR, dermatology clinics of 
Emory Healthcare and Grady Healthcare, community dermatology practices in metropolitan 
Atlanta, and self-referrals through the Lupus Foundation of America, Georgia Chapter.
Participants recruited as CCLE went through a diagnosis validation process that included 
medical records review, physician-assessment, and skin-pictures review. To be classified as 
CCLE, patients must have had a well-documented diagnosis of DLE, LEP, or LET by their 
attending board-certified dermatologist, or a skin-examination and/or photographs 
compatible with those CCLE subtypes according to the study’s dermatologist (LA) 
assessment. Because this study focuses on primary CCLE, we excluded participants with a 
rheumatologist-documented diagnosis of SLE or those who fulfilled >4 American College of 
Rheumatology criteria for SLE [26].
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As part of GOAL data collection, validated patient-reported tools on a variety of social 
determinants of health and patient-centered outcomes are assessed annually. In this study, we 
analyzed data collected for baseline assessment.
2.2 Measures
2.2.1 Depression—We used the Patient Reported Outcomes Measurement Information 
System (PROMIS) Depression SF-8a to assess depression. PROMIS are generic instruments 
designed to be applicable across populations and medical conditions [27]. Because their 
flexibility and precision, several PROMIS measures have been evaluated in racially diverse 
samples with lupus, showing adequate reliability and validity [27–29]. PROMIS Depression 
was adopted by the Diagnostic and Statistical Manual of Mental Disorders (5th ed.; DSM-5) 
[30]. PROMIS Depression raw scores (range 8-40) were converted to standardized T-scores 
(range 0-100; population mean 50; standard deviation [SD] 10) through the HealthMeasures 
Scoring Service [31]. Higher scores indicate greater frequency of depressive symptoms. For 
this study, we used the PROMIS Depression cutoff scores estimated to correspond with the 
Patient Health Questionnaire-9 (PHQ-9) legacy measure through PROsetta Stone linking 
methodology [32, 33]. A PROMIS T-score ≥60 was used to define positive depression, 
corresponding with the PHQ-9 cutoff ≥10. A positive depression screen was further 
categorized as moderate (PROMIS T-scores 60-<65.9), and moderately severe to severe 
depressive symptoms PROMIS T-score ≥66), corresponding with PHQ-9 cutoff scores 
10-14, and ≥15, respectively [32].
2.2.2 Demographics—Age, disease duration, gender, ethnicity, and educational 
attainment were self-reported.
2.2.3 Socioeconomic Resources—We assessed resources that may protect against 
depression, including marital status, employment, social support, and living above the 
poverty level [34]. PROMIS Social Support tools were used to assess emotional (confidant 
relationships or feelings validation), instrumental (assistance with materials, tasks, or 
cognition), and informational (advice or assistance) support [35]. PROMIS uses 
standardized T-scores (range 0-100; population mean 50; SD10) with higher T-scores 
representing more of the concept being measured. Living above the poverty level was 
calculated using the U.S. Census Bureau’s 2011 estimates as cutoff for 100% poverty 
threshold.
2.2.4 Healthcare Factors—We assessed insurance and healthcare usage in the last year 
(visits to primary care physician [PCP], rheumatology, dermatology, and psychological 
counseling referral). Physician-patient interactions have been found to be associated with 
depression and disease severity in SLE [36, 37]. Consequently, we used the interpersonal 
processes of care (IPC-29) survey to assess patients’ reports about three domains: physician-
patient communication, shared decision-making, and physician/staff interpersonal style [38]. 
IPC-29 uses 5-point Likert scale questions that are scored as 7 separate scales [38, 39]. 
Scales represent positive (e.g. elicited patient’s concerns) or negative (e.g. hurried 
communication) interactions with providers or staff. Higher scores (range 1-5) indicate 
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higher frequency of the construct (e.g. more frequent reports of elicited patient’s concerns 
[positive construct], or hurried communication [negative construct]) [38].
2.2.5 Disease-Related Factors—We used Skindex-29+, a modified version of the 
validated Skindex-29 (Skindex © MM Chren, 1997) [40–42] to assess skin-related quality of 
life. Skindex-29+ is a 5-point Likert scale that uses 29 items to measure skin-related QoL 
(symptoms, emotions, functioning), and 3 questions on CLE-specific (photosensitivity and 
alopecia) domains [21]. Scores for each subscale range from 0 (never) to 100 (all the time), 
with higher scores indicating worse QoL. Permission to use Skindex-29+ was provided by 
Mapi Research Trust [43].
2.3 Statistical Analysis
Statistical Analysis Software (SAS) Version 9.4 was used for data analysis. Data were 
summarized using frequency for categorical variables and mean (SD) for continuous 
variables. Differences in depression means by sociodemographic and healthcare factors were 
tested using two-tailed, two-sample t-tests, or ANOVA. Associations between depression 
with demographics, socioeconomic, healthcare, and disease-related factors were explored 
using univariate logistic regression analyses. Multivariable regression analyses were then 
conducted using a purposeful selection process of covariates, with an entry criterion of 
p<0.20 based on univariate analysis. Purposeful selection was used to help guide the 
retention of significant covariates, given the exploratory nature of the study [44]. Moreover, 
we used bootstrap bagging methods to create a parsimonious model [45]. The bootstrap 
sample was analyzed using forward stepwise logistic regression with an entry criterion of 
p<0.20 and a retention criterion of p<0.05. Covariates were retained in the final model if 
they appeared in at least 45% of the models. Odds ratios (OR) with 95% confidence 
intervals (CI) were reported as measures of association.
3. Results
3.1 Study Population
Among 125 primary CCLE patients enrolled by August 2017, 106 completed the PROMIS 
Depression questionnaire and were included in this study. Descriptive characteristics are 
shown in Table 1. Our sample was majority female (86.8%) and Black/non-White (85.8%). 
The mean age and disease duration were 51.1 years old and 10.6 years, respectively. 
Educational attainment was nearly evenly distributed between ≤high school (44.8%) and 
some college or more (55.2%). Approximately one-fourth (24.5%) was married or lived with 
a partner. Nearly half (42.9%) were unemployed or disabled; 53.9% lived above the poverty 
threshold; 28.2% and 22.3% had private or Medicare insurance, 15.5% received Medicaid, 
8.7% had both Medicare and Medicaid, and 25.2% were uninsured. Patients scored highest 
in CLE-specific and emotional Skindex-29+ measures and lowest in functioning. Nearly 
90% of patients saw a PCP in the previous year, but only 11.4% were referred to 
psychological counseling. We did not find statistically significant differences in any 
independent variables between depression survey respondents (n=106) and non-respondents 
(n=19).
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3.2 Depression Prevalence and Symptoms Severity
Twenty-eight participants (26.4%) screened positive for depression (T-score≥60), with 18 
(17%) reporting moderate (T-score 60-65.9) and 10 (9.4%) moderately severe or severe (T-
score≥66) depressive symptoms. Only 8 (29%) of those with moderate to severe depressive 
symptoms were referred to psychological counseling in the last year (data not shown). The 
average PROMIS Depression T-score for the overall cohort was 53.7 (SD 9.94).
3.3 Depression Scores by Independent Factors
Depression T-scores were significantly higher in patients younger than 60 and those with 
educational attainment ≤high school (Table 2). Depression scores were significantly lower in 
patients who were married/living with a partner, were employed/retired, lived above poverty 
status, or had insurance. Scores were also lower in patients who visited a PCP in the last 
year, though the difference was not statistically significant (p=0.06). No significant 
differences were found based on dermatologist or rheumatologist visits in the last year. 
Depression scores were significantly higher in patients who visited a psychiatrist or had 
been referred to psychological counseling in the last year. Patients whose disease duration 
ranged between 10-19 years had the highest depression scores.
Table 3 depicts the description of independent factors by depression and the univariate 
analyses results. No statistically significant associations were found between depression and 
demographic factors. Among social resources, being employed was inversely associated 
with depression (OR=0.24, p<0.01). Patients with higher scores across all social support 
types were less likely to be depressed: instrumental (OR=0.94, p=0.01), informational 
(OR=0.91, p<0.01), and emotional (OR=0.86, p<0.01) per 5 unit increase. Insured patients 
and those who visited a PCP in the last year were at lower risk of depression (OR=0.23, 
p<0.01; and OR=0.16, p<0.01, respectively). No significant differences were found for 
annual dermatology, psychiatry, or rheumatology visits. Depression was directly associated 
with worse reports of staff disrespect (OR=2.30, p=0.01) and inversely associated with better 
reports of physicians explaining labs/medications (OR=0.56, p=0.01). Among disease-
related factors, Skindex-29+ symptoms, functioning, and CLE-specific domains were 
significantly associated with depression (ORs 1.04, p<0.01).
The full multivariate model (Table 4) included variables with p<0.20 in univariate 
regression. After controlling for covariates, emotional support and physicians explaining 
labs/medications remained inversely associated with depression. A higher IPC-29 score of 
perceived office staff disrespect was associated with higher depression risk. In the 
parsimonious model, emotional support remained inversely associated with depression 
(OR=0.48, p<0.01) and worse report of staff disrespect increased the risk (OR=2.35, 
p=0.04).
4. Discussion
In a population-based cohort of predominantly Black patients with primary CCLE from the 
Southeast U.S., 26.4% screened positive for moderate to severe depressive symptoms. This 
prevalence rate is higher than those reported by the CDC among a representative sample of 
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household residents drawn from the metropolitan Atlanta area (7.4%), as well as for females 
(5.6%) and Black individuals (4.9%) in that sample [46]. Our rate is also higher than those 
reported among European dermatology patients (10.1-14.1%) [1,3], and atopic dermatitis 
(17.1%) [47]; and comparable to those for CLE (26.5 to 29.7%) [2, 15], dermatomyositis 
(26.8%) [2], and SLE (20-47%) [7,9].
Depression in people with chronic conditions has been associated with adverse health 
behaviors, which in turn may lead to poor disease outcomes and increase healthcare 
utilization and costs [48]. As clinical depression is treatable and screening improves the 
accurate identification of patients with depression in primary care settings, the U.S. 
Preventive Services Task Force (USPSTF) recommends early detection, intervention and 
treatment to the general adult population [49]. In subspecialty clinics, depression screening 
and mental care referral can be challenging and may best be tackled integrating the social, 
psychological and biological aspects of the of the patient’s experience.
Our findings underscore a biopsychosocial context associated with depression in a 
predominantly Black population with primary CCLE. As opposed to previous studies that 
reported a higher burden of depression in females and racial minorities from the general 
population [46, 50, 51], we did not find significant differences in either the risk or the 
severity of depressive symptoms by gender or race in our CCLE sample. A plausible 
explanation is the low numbers of White subjects and males in our cohort, which in turn 
reflects the demographic disparities of the patient population affected by primary CCLE in 
the Southeastern US [22]. We found that participants aged <60 had higher depression scores 
than those ≥60, paralleling the age-related psychological vulnerability described in the 
general population [52, 53]. Interestingly, patients with longer disease duration (10-19 years) 
had higher depression scores, contrasting with previous reports in patients with SLE, who 
had higher depression incidence within 3 years of diagnosis [9]. Our results suggest a link 
between social and biological factors that might lead to poorer disease control and 
increasing depressive symptoms in this population. Disease-related factors as measured by 
Skindex-29+ symptom severity, functioning, and lupus-specific domains were significantly 
associated with depression in the univariate analysis, consistent with previous reports of 
psychiatric comorbidity impacting QoL in skin disease and lupus outcomes in general [54, 
55]. However, after controlling for other covariates, skin-related QoL no longer remained 
significant, suggesting that in this population, the social context may have a stronger impact 
on psychological disorders than skin-specific factors.
Socioeconomic resources (being married/living with a partner, employed, having health 
insurance) were associated with lower depression scores. These results are consistent with 
previous findings in the general population that support an association between depression 
and unemployment [56]. Because insurance is often provided as an employment benefit, 
these factors may be conflated. In consistency with recent studies in the general population, 
as well as among patients with SLE and other skin conditions, our findings suggest a 
protective role of social support on depression [57–59]. While in patients with SLE physical 
health limitations, unemployment, and lack of understanding of the disease by others may 
lead to social isolation and depression[58]; social stigma, low self-steem related to physical 
appearance, and limitations to develop outdoor recreational activities may pose significant 
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phychological challenges and barriers to interacting with others in the CCLE population [60, 
61]. Our multivariate analysis showed that emotional support was the only social resource 
that independently reduced the risk of depression, suggesting that psychosocial interventions 
involving patients, as well as patients’s family and friends may be beneficial to prevent or 
reduce depressive symptoms in patients with CCLE.
This study also highlights the importance of understanding the clinical environment and 
encounters as potentially modifiable factors for CCLE patients with depressive symptoms. 
After adjusting for covariates, poorer quality of interpersonal care processes, specifically 
perceived staff disrespect increased the odds of depression. In contrast, better physician 
communication was shown to be protective. Previous reports have described a negative 
impact of social stigma on the mental health of people with skin conditions [60, 62], and on 
the same vein, our findings suggest that perceived discrimination in the healthcare setting 
can potentially contribute to depressive symptoms in patients with CCLE. However, given 
the cross-sectional nature of our data, we cannot rule out that depression may negatively 
influence patients’ perceptions about their encounters with providers and office staff [63, 
64]. Elucidating the direction and underpinning mechanisms of these associations are of 
interest as they are potentially modifiable through staff training and provider education.
We found lower scores and reduced depression risk among CCLE patients who visited a 
PCP in the last year, underscoring the potentially valuable role of the primary care team in 
mental health management. This effect was not seen across other specialties, suggesting that 
primary care visits may protect against depression possibly due to the perception of the PCP 
as a component of the patient’s support system. Moreover, PCPs are more likely to 
implement systematic early depression screening and management interventions, including 
antidepressant medication and referrals to psychotherapy, social, and care coordination 
resources [65]. As depression is a major factor associated with low medication adherence in 
lupus patients [66] and recent findings indicate that CLE patients with depression incur in 
higher utilization and costs related to Emergency Department visits and hospitalizations, 
compared to those without depression [15], connecting depressed CCLE patients to mental 
healthcare providers could be another area for care optimization in dermatology practices.
Our study has limitations, including the sample size, which may not have enough power to 
find statistically significant differences in relation to the number of covariates that were 
examined. The cross-sectional design does not allow to assess for causality. Moreover, 
because this is a population-based cohort, we primarily collected patient-reported data and 
did not conduct physician assessments of cutaneous activity and chronicity, location of 
lesions, or comorbidities, all which can potentially be linked to depression [15, 67]. 
However, we assessed skin-related QoL as a surrogate of disease severity, which has been 
shown to be a stronger predictor of psychiatric morbidity than physician-rated clinical 
severity in patients with cutaneous conditions [3]. Similarly, because we used a self-reported 
depression tool, some of those who screened positive for moderate to severe depressive 
symptoms may not be diagnosed with clinical depression. Moreover, this is a prevalent 
cohort and we were not able to examine time-dependent confounders that may have occurred 
before enrollment.
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Our study has several strengths. First, to our knowledge, this is the first description of 
depression in a large and predominantly Black population with primary CCLE. Prior studies 
that assessed psychiatric comorbidity in CLE included patients with a heterogeneous 
spectrum of CLE conditions or cases with systemic manifestations of lupus [2, 14–16, 20]. 
Given that depression is highly prevalent and potentially associated with inflammation in 
SLE [8–9], the mental health of CLE may be influenced not only by the wide variety of 
cutaneous phenotypes but also by the presence of systemic symptoms. By assessing patients 
with primary CCLE (without systemic involvement), we establish the foundation to identify 
aspects of depression that may be more specific to CCLE subpopulations, where illness is 
primarily characterized by visible and permanent skin lesions. In addition, our study is 
demographically unique, consisting of majority Black women and a wide range of 
socioeconomic levels and degrees of social support, providing broader reflection of the 
patient population affected by CCLE in the US [22].
5. Conclusion
Our study underscores the high prevalence of depressive symptoms in a predominantly 
Black cohort of individuals with primary CCLE. We identified individual, clinical, and 
social factors that can serve to inform future research and interventions to address 
depression in patients with CCLE. Our data suggest that in addition to depression screening 
and management, interventions to train healthcare staff on courteous interpersonal 
interactions and enhanced emotional support throughout patients’ networks may contribute 
to reduce psychiatric comorbidity in vulnerable populations with primary CCLE. These 
results encourage hypothesis generation and further study regarding biological and 
psychosocial determinants of mental health in CCLE.
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Key Points
• Little is known about depression in chronic cutaneous lupus erythematosus 
(CCLE).
• Over a quarter of patients with primary CCLE reported moderate to severe 
depressive symptoms.
• Depressive symptoms in this predominantly Black population were more 
likely related to psychosocial interactions than socioeconomic or disease-
related factors.
• Patients with CCLE may benefit from mental healthcare, effective 
interpersonal interactions in the clinical setting, and emotional support.
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Table 1.
Description of 106 Patients with Chronic Cutaneous Lupus Erythematosus
Characteristic Value
Age at Survey, mean (SD), years 51.1 (13.3)
Disease Duration, mean (SD), years 10.6 (9.0)
Female Sex (%) 92 (86.8)
Race (%)
   Black/African-American or Non-White* 91 (85.8)
   White 15 (14.2)
Education Level (n = 105) mean (SD), years (%) 13.5 (2.8)
   High School or Less, ≤12 47 (44.8)
   Some College, 13-15 25 (23.8)
   College or Above, ≥16 33 (31.4)
Marital Status (%)
   Married or Living with Partner 26 (24.5)
   No PartnerΔ 80 (75.5)
Current Work Status (n = 105) (%)
   Employed (Full or Part-Time) 40 (38.1)
   Retired/Homemaker/Student 20 (19.0)
   Unemployed/Disabled 45 (42.9)
Living above the Poverty Line^ 48 (53.9)
Insurance Status (n = 103) (%)
   Uninsured 26 (25.2)
   Private 29 (28.2)
   Medicare 23 (22.3)
   Medicaid 16 (15.5)
   Medicare/Medicaid 9 (8.7)
Skin-Specific Quality of Life (Skindex-29+) (SD)
   Emotions 55.3 (31.8)
   Symptoms 48.2 (24.9)
   Functioning 37.3 (30.7)
   CLE-Specific Questions 65.2 (29.2)
Seen Provider in Last 12 Months (%)
   Primary Care Physician 95 (89.6)
   Dermatologist 70 (66.7)
   Psychiatrist 21 (20.0)
   Rheumatologist 64 (61.5)
   Referred to Psychological Counseling 12 (11.4)
PROMIS Depression Score, mean (SD) 53.7 (9.9)
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Characteristic Value
   Negative (T-score <60) 78 (73.6)
   Positive (T-score ≥60) 28 (26.4)
Values indicate N (%), unless otherwise specified.
*
non-White includes: American Indian (n=1), Asian (n=2), Hispanic/Latino (n=2), and other (n=1).
ΔSeparated, divorced, widowed, or never married;
^
Data collected for 89 participants.
Abbreviations: SD, standard deviation; CLE, cutaneous lupus erythematosus.
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Table 2.
Severity of Depressive Symptoms by Sociodemographic, Healthcare and Disease-Related Factors
Variable Subjects
N Depression Score
^
mean (SD)
p-value
Demographics
  Gender
   Male 14 53.4 (6.97) 0.90
   Female 92 53.8 (10.4)
  Age at Survey (years)
   ≤39 23 55.9 (10.2) <0.01
   40-59 59 55.1 (9.77)
   ≥60 24 48.1 (8.35)
  Race
   Black & non-White* 91 54.2 (9.84) 0.21
   White 15 50.7 (10.5)
  Educational attainment (years)
   High school or Less (≤12) 47 55.7 (9.74) 0.02
   Some College (13-15) 25 54.5 (10.6)
   College or Above (≥16) 33 49.8 (8.60)
Socioeconomic Resources
  Marital Status
   Married/Living with Partner 26 49.6 (8.97) 0.01
   No PartnerΔ 80 55.0 (9.93)
  Work Status
   Employed (Full/Part-Time) 40 51.3 (8.37) <0.01
   Retired/Homemaker/Student 20 49.0 (9.48)
   Unemployed/Disabled 45 58.1 (10.0)
  Living above the Poverty Line
   Yes 48 51.2 (10.5) 0.04
   No 41 55.5 (8.84)
Healthcare Factors
  Insurance Status
   Insured 80 52.4 (9.77) 0.02
   Uninsured 26 57.8 (9.56)
  Type of Insurance
   Medicaid 26 54.2 (10.6) 0.05
   Medicare 26 50.2 (9.96)
   Private 28 52.8 (8.72)
   Uninsured 26 57.8 (9.56)
Visited a Primary Care Physician◊
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Variable Subjects
N Depression Score
^
mean (SD)
p-value
   Yes 95 53.1 (9.65) 0.06
   No 11 59.0 (11.4)
  Visited a Dermatologist◊
   Yes 70 55.8 (8.95) 0.15
   No 35 55.8 (11.7)
  Visited Psychiatrist◊
   Yes 21 59.7 (9.99) <0.01
   No 84 52.3 (9.47)
  Visited Rheumatologist◊
   Yes 40 54.4 (9.72) 0.41
   No 64 52.7 (10.6)
Referred to Psychological Counseling◊
   Yes 12 63.1 (8.5) <0.01
   No 93 52.5 (9.5)
Disease-Related Factors
Disease Duration (years)
   ≤4 37 50.6 (8.96) 0.04
   5-9 25 54.7 (9.63)
   10-19 24 58.1 (9.64)
   ≥20 18 52.8 ± 11.6
^
PROMIS Depression SF8a T-score (higher values indicate greater depression symptoms; cutoff T-score for moderate to severe depression is ≥60);
ΔSeparated, divorced, widowed, or never married;
◊in the last 12 months.
Abbreviations: SD, standard deviation.
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Table 3.
Factors Associated with Depression in Chronic Cutaneous Lupus Erythematosus
Variable DepressionΔ Odd Ratio^ (95%CI) P
value
Yes (n=28) No (n=78)
Demographics
  Age (years), mean ± SD 47.4 ± 11.1 52.4 ± 13.9 0.87 (0.74 - 1.02) 0.09
  Disease Duration (years), mean ± SD 11.2 ±7.5 10.4 ± 9.5 1.05 (0.83 - 1.34) 0.66
  Gender (female) 25 (89.3) 67 (85.9) 1.37 (0.35 - 5.31) 0.65
  Black/Non-White Race 26 (92.9) 65 (83.3) 2.60 (0.55 - 12.33) 0.23
  Graduated High School 13 (48.2) 45 (57.7) 0.68 (0.28 - 1.64) 0.39
Socioeconomic Resources
  Married/Living with Partner 3 (10.7) 23 (29.5) 0.29 (0.08 - 1.05) 0.06
  Currently Employed 9 (32.1) 51 (66.2) 0.24 (0.10 - 0.61) <0.01
  Living Above the Poverty Level 9 (42.9) 39 (57.4) 0.56 (0.21 - 1.50) 0.25
  PROMIS Instrumental Support (5-unit ↑) 47.2 ± 10.0 53.0 ± 9.64 0.94 (0.90 - 0.99) 0.01
  PROMIS Informational Support (5-unit ↑) 43.4 ± 12.0 54.9 ± 9.74 0.91 (0.87 - 0.95) <0.01
  PROMIS Emotional Support (5-unit ↑) 42.9 ± 9.59 55.3 ± 8.06 0.86 (0.81 - 0.92) <0.01
Healthcare Factors
  Currently Insured 15 (53.6) 65 (83.3) 0.23 (0.09 - 0.60) <0.01
  Visited Primary Care Physician◊ 21 (75.0) 74 (94.9) 0.16 (0.04 - 0.61) <0.01
  Visited Dermatologist◊ 15 (53.6) 55 (71.4) 0.46 (0.19 - 1.13) 0.09
  Visited Psychiatrist◊ 7 (25.0) 14 (18.2) 1.50 (0.53 - 4.21) 0.44
  Visited Rheumatologist◊ 15 (53.6) 49 (64.5) 0.64 (0.26 - 1.53) 0.31
  IPC-29 Hurried Communication (1-unit ↑) 2.12 ± 0.85 1.84 ± 0.87 1.43 (0.83 - 2.33) 0.16
  IPC-29 Elicited Patient’s Concerns (1-unit ↑) 3.80 ± 0.88 4.14 ± 0.81 0.61 (0.37 - 1.03) 0.07
  IPC-29 Explained Labs/Meds (1-unit ↑) 3.53 ± 1.03 4.14 ± 0.97 0.56 (0.37 - 0.87) 0.01
  IPC-29 Shared Decision Making (1-unit ↑) 2.98 ± 1.42 3.34 ± 1.31 0.81 (0.59 - 1.13) 0.21
  IPC-29 Compassionate/Respectful (1-unit ↑) 3.73 ± 0.93 4.04 ± 0.96 0.73 (0.47 - 1.13) 0.16
  IPC-29 Discriminated (Race/SES) (1-unit ↑) 1.61 ± 0.59 1.36 ± 0.67 1.71 (0.89 - 3.27) 0.11
  IPC-29 Office Staff Disrespect (1-unit ↑) 1.63 ± 0.73 1.26 ± 0.58 2.30 (1.19 - 4.47) 0.01
Disease-Related Factors
  Skindex-29+ Symptoms 63.6 ± 20.9 42.6 ± 24.0 1.04 (1.02 - 1.06) <0.01
  Skindex-29+ Functioning 60.0 ± 28.7 29.1 ± 27.3 1.04 (1.02 - 1.05) <0.01
  Skindex-29+ Lupus Measure 82.7 ± 22.1 58.9 ± 29.0 1.04 (1.02 - 1.06) <0.01
  Disease Duration (years), mean ± SD 11.2 ± 7.5 10.4 ± 9.5 1.05 (0.83 - 1.34) 0.66
ΔValues for each variable indicate N (%) unless otherwise specified;
◊in last 12 months;
^
calculated with logistic regression analysis.
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Cutoff score for depression is based on a T-score ≥60 for the PROMIS Depression SF8a. IPC-29: Interpersonal Processes of Care-29 Survey; SES: 
socioeconomic status. Abbreviations: SD, standard deviation.
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Table 4.
Factors Associated with Depression. Multivariate Analysis
Full Model Parsimonious Model*
Variable Odds Ratio
(95% CI)
p-value Odds Ratio
(95% CI)
p-value
Demographics
  Age (5-year ↑) 0.97 (0.68 - 1.39) 0.86
Socioeconomic Resources
  Married/Living with Partner 0.98 (0.09 - 11.0) 0.98
  PROMIS Instrumental Support (5-unit ↑) 1.02 (0.56 -1.84) 0.95
  PROMIS Informational Support (5-unit ↑) 1.19 (0.65 - 2.18) 0.57
  PROMIS Emotional Support (5-unit ↑) 0.38 (0.15 - 0.95) 0.04 0.48 (0.35 - 0.66) <0.01
Healthcare Factors
  Currently Insured 0.26 (0.04 - 1.84) 0.18
  Visited Primary Care Physician◊ 0.10 (0.01 - 1.49) 0.10
  Visited Dermatologist◊ 0.46 (0.08 - 2.49) 0.37
  IPC-29 Hurried Communication (1-unit ↑) 0.46 (0.11 - 1.86) 0.27
  IPC-29 Elicited Patient Concerns (1-unit ↑) 0.96 (0.28 - 3.24) 0.94
  IPC-29 Explained Labs/Meds (1-unit ↑) 0.35 (0.12 - 1.04) 0.06
  IPC-29 Compassionate/Respectful (1-unit ↑) 1.49 (0.30 - 7.49) 0.63
  IPC-29 Discriminated (Race/SES) (1-unit ↑) 1.96 (0.46 - 8.44) 0.36
  IPC-29 Office Staff Disrespect (1-unit ↑) 4.32 (1.16 – 16.1) 0.03 2.35 (1.06 – 5.17) 0.035
Disease-Related Factors
  Skindex-29+ Symptom (1-unit ↑) 1.01 (0.95- 1.07) 0.73
  Skindex-29+ Functioning (1-unit ↑) 1.01 (0.96 - 1.06) 0.81
  Skindex-29+ Lupus Measure (1-unit ↑) 1.02 (0.98 - 1.07) 0.32
*Variables were selected if they met >45% reliability by bootstrap bagging methods.
Abbreviations: CI, confidence interval; IPC-29, Interpersonal Processes of Care-29 Survey;
◊in last 12 months.
Cutoff score for depression is based on a T-score ≥60 for the PROMIS Depression SF8a.
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